Increasing progranulin levels and blockade of the ERK1/2 pathway: Upstream and downstream strategies for the treatment of progranulin deficient frontotemporal dementia-Reference-Cited by-同舟云学术

Increasing progranulin levels and blockade of the ERK1/2 pathway: Upstream and downstream strategies for the treatment of progranulin deficient frontotemporal dementia

Published:2015-03 Issue:3 Volume:25 Page:386-403
ISSN:0924-977X
Container-title:European Neuropsychopharmacology
language:en
Short-container-title:European Neuropsychopharmacology

Author:

Alquezar Carolina,Esteras Noemí,Encarnación Ana de la,Moreno Fermín,de Munain Adolfo López,Martín-Requero Ángeles

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology

Reference89 articles.

1. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers;Adjei;J. Clin. Oncol. Official Journal of the American Society of Clinical Oncology,2008

2. MEK and the inhibitors: from bench to bedside;Akinleye;J. Hematol. Oncol.,2013

3. Inactivation of CDK/pRb pathway normalizes survival pattern of lymphoblasts expressing the FTLD-progranulin mutation c.709-1G>A;Alquezar;PLoS One,2012

4. Alteration in cell cycle-related proteins in lymphoblasts from carriers of the c.709-1G>A PGRN mutation associated with FTLD-TDP dementia;Alquezar;Neurobiol. Aging,2011

5. PGRN haploinsufficiency increased Wnt5a signaling in peripheral cells from FTLD-progranulin mutation carriers;Alquezar;Neurobiol. Aging,2014

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progranulin Deficiency Induces Mitochondrial Dysfunction in Frontotemporal Lobar Degeneration with TDP-43 Inclusions;Antioxidants;2023-02-25

2. Biomarkers in frontotemporal dementia: a narrative review;Drugs of the Future;2023-01

3. FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders;Pharmaceuticals;2022-12-13

4. Posttranslational modifications of TDP-43;TDP-43 and Neurodegeneration;2022

5. TDP-43 and neurodegenerative diseases;TDP-43 and Neurodegeneration;2022